



Adverse Drug Events by Sex After Adjusting for Baseline Rates of Drug Use

Tamara Rushovich, MPH; Annika Gompers, MPhil; Jeffrey W. Lockhart, PhD; Ife Omidiran, BA; Steven Worthington, PhD; Sarah S. Richardson, PhD; Katharine M. N. Lee, PhD

Introduction

Although they have known limitations,¹ spontaneous reporting pharmacovigilance databases like the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and World Health Organization VigiBase are widely cited as evidence for claims that women experience adverse drug events (ADEs) at as high as twice the rate of men.^{2,3} Pharmacokinetics and pharmacodynamics are typically used to explain these sex differences²; however, many factors could influence the distribution of ADE reports by sex, including well-known disparities in the rates at which men and women use prescribed drugs.⁴ This study examined ADEs reported by sex in the FAERS database after adjusting for drug use by men and women. Information regarding how sex and gender are conceptualized in this study and its data sources appears in [Supplement 1](#).

+ Supplemental content

Author affiliations and article information are listed at the end of this article.

Methods

This cross-sectional study used publicly available, deidentified data and was determined by the Harvard Institutional Review Board not to be research involving human participants. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

In this study, ADE data from FAERS were matched with drug use data from the Medical Expenditure Panel Survey (MEPS), a nationally representative survey of US health care use, for the years 2014 to 2019.⁵ Bayesian general linear models were used to estimate (1) the Pearson correlation coefficient (r) between the proportion of people using a drug who were females and proportion of ADE reports in FAERS for that drug filed by females (**Figure 1**) and (2) the association between the natural log of the number of ADE reports for a drug and the natural log of the number of people using that drug (eMethods in [Supplement 1](#)). Data management and analysis were conducted in Python software version 3.10.9 (Python Software Foundation) and R version 4.2.3 (R Project for Statistical Computing).

Results


There were 19 940 532 ADEs reported in FAERS during the study, 12 622 357 (63.3%) of which were experienced by females. Reports in FAERS were highly correlated with between-sex variation in baseline rates of drug use ($r = 0.74$; 95% highest posterior density interval [HPDI], 0.70 to 0.78). In a model not adjusting for estimated drug use, the median number of reports of ADEs experienced by females was 45.1% (95% HPDI, 4.6% to 104.3%) higher than the number experienced by males. In a model adjusting for estimated drug use, the median number of reports of ADEs experienced by females reduced to 15.0% (95% HPDI, -15.8% to 57.6%) higher than that of males, a 3-fold decrease on average, and a sex difference of 0 became plausible (**Figure 2**).

With the unadjusted model, the probability of a median sex difference ranging from -5% to 5% (ie, close to 0) was 2.2%, whereas the probability of a sex difference in which the median number of ADEs is 50% to 100% higher for females compared with males was 39.3%. After adjusting for drug

Open Access. This is an open access article distributed under the terms of the CC-BY License.


use, the probability of a sex difference close to 0 (ie, -5% to 5% higher median number of ADEs for females) was 17%, whereas a sex difference of 50% to 100% higher ADEs in females compared with males was reduced to 4.9% (Figure 2).

Figure 1. Correlation Between Sex Disparities in ADE Reports and Sex Disparities in Drug Use



ADE reports by sex are highly correlated with sex disparities in rates of drug use (r , 0.74; 95% highest posterior density intervals, 0.70-0.78). Data are included for all 356 drugs that were in both data sets and where at least 50 people were observed. FAERS indicates US Food and Drug Administration Adverse Event Reporting System; MEPS, Medical Expenditure Panel Survey.

Figure 2. Posterior Distributions of Sex Differences in Reported Adverse Drug Events (ADEs) Before and After Adjustment for Drug Use



The area under the curves that is shaded in orange represents the probability of a median sex disparity between -5% to 5%, while the area under the curves that is shaded in blue represents the probability of a median sex disparity between 50% to 100%. The black lines at the bottom of the curves represent 95% highest posterior density intervals, and

the black points within those lines denote the medians of the posterior distributions. After adjustment for drug use (B), the probability of a median sex disparity between 50% to 100% reduces from 39.3% to 4.9%.

Discussion

In this cross-sectional study, adjusting pharmacovigilance data from FAERS with nationally representative data on sex disparities in usage of drugs from MEPS greatly attenuated the apparent sex disparity in ADE reporting, reducing the gap in the median number of ADEs for women compared with men from 45.1% to 15.0%. The commonly cited claim that females experience 1.5 to 2 times the number of ADEs as males,⁶ was found to be highly unlikely, with a probability of less than 5% after accounting for drug usage. This study had limitations inherent to FAERS and MEPS data, including potential selection bias due to voluntary reporting, which prohibits the calculation of ADE incidence rates. Nevertheless, after accounting for underlying drug use, reported numbers of ADEs were similar between males and females when looking across drugs, suggesting that sex disparities in drug use may largely explain observed sex disparities in ADEs, bolstering evidence from a limited number of prior studies that have accounted for drug use in analyses of sex disparities in ADEs in pharmacovigilance data.⁵

ARTICLE INFORMATION

Accepted for Publication: July 7, 2023.

Published: August 21, 2023. doi:10.1001/jamanetworkopen.2023.29074

Open Access: This is an open access article distributed under the terms of the [CC-BY License](#). © 2023 Rushovich T et al. *JAMA Network Open*.

Corresponding Author: Tamara Rushovich, MPH, Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Boston, MA 02115 (trushovich@harvard.edu).

Author Affiliations: Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts (Rushovich); Emory University Rollins School of Public Health, Atlanta, Georgia (Gompers); Department of Sociology, University of Chicago, Chicago, Illinois (Lockhart); Harvard University, Cambridge, Massachusetts (Omidiran); Institute for Quantitative Social Science, Harvard University, Cambridge, Massachusetts (Worthington); Harvard University, Cambridge, Massachusetts (Richardson); Tulane University, New Orleans, Louisiana (Lee).

Author Contributions: Ms Rushovich and Dr Worthington had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Ms Rushovich, Ms Gompers, and Dr Lockhart had equal contribution to the work.

Concept and design: Rushovich, Gompers, Lockhart, Richardson, Lee.

Acquisition, analysis, or interpretation of data: Rushovich, Gompers, Lockhart, Omidiran, Worthington, Lee.

Drafting of the manuscript: Rushovich, Gompers, Lockhart, Omidiran, Richardson, Lee.

Critical review of the manuscript for important intellectual content: Worthington, Lee.

Statistical analysis: Rushovich, Lockhart, Omidiran, Worthington.

Obtained funding: Richardson.

Administrative, technical, or material support: Lockhart, Omidiran, Richardson, Lee.

Supervision: Lockhart, Richardson, Lee.

Conflict of Interest Disclosures: Dr Richardson reported receiving grants from Robert Wood Johnson Foundation during the conduct of the study. No other disclosures were reported.

Funding/Support: This study was supported by grant 79892 from the Robert Wood Johnson Foundation's Pioneering Ideas program. Dr Lockhart was supported by a grant from the James S. McDonnell Foundation.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The views expressed here do not necessarily reflect the views of the funders.

Data Sharing Statement: See [Supplement 2](#).

Additional Contributions: The authors thank Alexander Borsa, BA (Sociomedical Sciences, Columbia Mailman School of Public Health) and Alexandra Fair, MA (African and African American Studies, Harvard University), for contributing to early literature reviews; Marina DiMarco, MA (History and Philosophy of Science, University of

Pittsburgh), for assistance with data acquisition; Marion Boulicault, PhD (Philosophy, University of Edinburgh) for assisting with conception and design, project management, and manuscript revisions; and Heather Shattuck-Heidorn, PhD (no current affiliation), for early conceptualization, project management, and data analysis. None of the individuals listed above received compensation for their contributions.

REFERENCES

1. Center for Drug Evaluation and Research. Questions and answers on FDA's Adverse Event Reporting System (FAERS). Food and Drug Administration. Published May 22, 2019. Accessed December 5, 2022. <https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers>
2. Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. *Biol Sex Differ*. 2020;11(1):32. doi:10.1186/s13293-020-00308-5
3. Tharpe N. Adverse drug reactions in women's health care. *J Midwifery Womens Health*. 2011;56(3):205-213. doi:10.1111/j.1542-2011.2010.00050.x
4. de Vries ST, Denig P, Ekhart C, et al. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: an explorative observational study. *Br J Clin Pharmacol*. 2019;85(7):1507-1515. doi:10.1111/bcp.13923
5. Davis KE. Sample design of the 2020 Medical Expenditure Panel Survey Insurance Component. Agency for Health Care Research and Quality. 2021. Accessed July 13, 2023. https://www.meps.ahrq.gov/data_files/publications/mr34/mr34.pdf
6. Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. *Br J Clin Pharmacol*. 1998;46(5):505-511. doi:10.1046/j.1365-2125.1998.00817.x

SUPPLEMENT 1.

eMethods.

SUPPLEMENT 2.

Data Sharing Statement